We are live on ! Find out more
AVDL

Avadel Pharmaceuticals
AVDL

Delisted

AVDL was delisted on the 11th of February, 2026.

Back to rankings

87 hedge funds and large institutions have $360M invested in Avadel Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 27 increasing their positions, 25 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 4

14% more capital invested

Capital invested by funds: $316M → $360M (+$44.6M)

4% more funds holding

Funds holding: 84 → 87 (+3)

8% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 25

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

97% less call options, than puts

Call options by funds: $37K | Put options by funds: $1.08M

Holders
87
Holders Change
+3
Holders Change %
+3.57%
% of All Funds
2.32%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
7
Increased
27
Reduced
25
Closed
4
Calls
$37K
Puts
$1.08M
Net Calls
-$1.05M
Net Calls Change
-$65K

Top Buyers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
+$17.8M
2
IHM
Iguana Healthcare Management
New York
+$4.25M
3
AC
Armistice Capital
New York
+$3.29M
4
GTC
Ghost Tree Capital
New York
+$2.94M
5
Morgan Stanley
Morgan Stanley
New York
+$2.21M

Top Sellers

Rank Fund Capital Flow
1
JGC
J. Goldman & Co
New York
-$6.2M
2
Millennium Management
Millennium Management
New York
-$5.83M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
-$4.96M
4
EA
Emerald Acquisition
Washington
-$3.53M
5
FPC
Falcon Point Capital
California
-$2.42M
Name Holding Trade Value Shares
Change 		Change in
Stake
PCM
51
Prelude Capital Management
New York
$307K +$324K +24,786 New
Geode Capital Management
52
Geode Capital Management
Massachusetts
$275K -$51.3K -3,929 -15%
CG
53
Cutler Group
California
$263K +$92.8K +7,104 +50%
VKH
54
Virtu KCG Holdings
New York
$240K +$253K +19,366 New
DekaBank Deutsche Girozentrale
55
DekaBank Deutsche Girozentrale
Germany
$235K – – –
Susquehanna International Group
56
Susquehanna International Group
Pennsylvania
$233K +$54.6K +4,178 +29%
CCM
57
Condor Capital Management
New Jersey
$208K – – –
Citigroup
58
Citigroup
New York
$197K +$22.3K +1,708 +12%
EMG
59
Ellington Management Group
Connecticut
$184K +$193K +14,800 New
Walleye Trading
60
Walleye Trading
New York
$165K +$132K +10,100 +316%
US Bancorp
61
US Bancorp
Minnesota
$155K – – –
Group One Trading
62
Group One Trading
Illinois
$148K +$53.7K +4,114 +53%
SIG
63
Stanford Investment Group
California
$146K – – –
SEI Investments
64
SEI Investments
Pennsylvania
$140K +$60.9K +4,658 +70%
Citadel Advisors
65
Citadel Advisors
Florida
$129K +$136K +10,423 New
BFM
66
Boothbay Fund Management
New York
$128K +$135K +10,300 New
BWP
67
Baldwin Wealth Partners
Massachusetts
$115K +$65.3K +5,000 +116%
IA
68
IFP Advisors
Florida
$105K – – –
Royal Bank of Canada
69
Royal Bank of Canada
Ontario, Canada
$75K -$1.44K -110 -2%
Bank of Montreal
70
Bank of Montreal
Ontario, Canada
$53K – – –
EDRH
71
Edmond de Rothschild Holding
Switzerland
$50K – – –
EDRS
72
Edmond de Rothschild (Suisse)
Switzerland
$50K – – –
CLOS
73
Compagnie Lombard Odier SCmA
Switzerland
$37K – – –
DADC
74
D.A. Davidson & Co
Montana
$37K – – –
AIM
75
Acrospire Investment Management
Illinois
$37K +$38.6K +2,955 New
1 2
3
4

AVDL Hedge Fund Activity: Q3 2016 in Review

87 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q3 2016, worth a combined $360M — up 14% from $316M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new AVDL positions and 4 closed out — a net gain of 3 holders — while 27 added to existing stakes and 25 trimmed.

The largest buyer was Perceptive Advisors, opening a new position worth an estimated $17.8M. The largest seller was J. Goldman & Co, cutting an estimated $6.2M.

  • 87 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q3 2016, up from 84 in Q2 2016.
  • Funds reported $360M of Avadel Pharmaceuticals stock for Q3 2016, up 14% quarter-over-quarter.
  • 7 funds opened new Avadel Pharmaceuticals positions in Q3 2016 and 4 closed out, a net change of +3 holders.
  • The largest Avadel Pharmaceuticals buyer in Q3 2016 was Perceptive Advisors, an estimated $17.8M added.
  • The largest Avadel Pharmaceuticals seller in Q3 2016 was J. Goldman & Co, an estimated $6.2M sold.

Based on aggregated 13F filings for Q3 2016.